B

BeOne

Global oncology therapeutics discovery, development, manufacturing

Senior Content Operations Specialist

Full-TimeUpdated on 10/15/2026
PLN164.2k - PLN205.2k
Mid, Senior
Bachelor's
Warsaw, Poland
HybridThree days per week in the Warsaw office and two days remote.
Data & AnalyticsData Management

About the job

Requirements
  • A bachelor's degree or an equivalent combination of education and relevant professional experience, preferably in Information Systems, Information Science, Marketing, Business Administration, Data Analytics, Communications, Life Sciences, or Digital Content Management or a related field.
  • At least four years of experience in content operations, digital asset management, marketing operations, or related roles, preferably within biotech, pharma, or life sciences.
  • Hands-on experience with Veeva Vault PromoMats or similar regulated content management systems; Veeva Vault certification is preferred.
  • A solid understanding of content lifecycle processes, including PRC/MRC review, approval, and compliance requirements.
  • Demonstrated experience managing digital asset management libraries, claims repositories, and metadata/taxonomy structures.
  • Strong analytical skills and experience translating data into actionable insights and reporting.
  • Experience with metadata standards, data governance, and data quality management.
  • Ability to operate effectively in a cross-functional, matrixed environment, collaborating with Commercial, Medical, Regulatory, Legal, and agency partners.
  • Detail orientation and strong organizational skills focused on accuracy, consistency, and data integrity.
  • Strong communication skills and ability to provide clear guidance and training to stakeholders on processes and systems.
  • Proactive, solution-oriented approach focused on continuous improvement and operational efficiency.
  • Strong working knowledge of Veeva Vault PromoMats, including digital asset management, claims, and content lifecycle workflows; digital asset management platforms and asset governance processes; and claims and references management systems in regulated environments.
  • Proficiency with metadata, taxonomy, and tagging frameworks; reporting and analytics tools such as Excel, Power BI, Tableau, or similar; and data analysis and data quality management practices.
  • Familiarity with PRC/MRC workflows and content review processes within Veeva Vault; content management system and omnichannel activation platforms; and modular content frameworks and reuse strategies.
  • Experience with collaboration and documentation tools such as Microsoft Teams, SharePoint, or Confluence, and with data extraction, reporting, and dashboard development.
  • Minimal travel is required, estimated at 0–10%, primarily for key workshops, training sessions, or team planning meetings.
Responsibilities
  • Manage day-to-day operations of digital asset management within Veeva Vault PromoMats, ensuring content is accurately ingested, tagged, classified, and maintained.
  • Enforce metadata, taxonomy, and naming conventions to ensure content discoverability, reuse, and compliance.
  • Maintain asset lifecycle governance, including version control, archival, expiration, and reuse eligibility.
  • Partner with content owners, agencies, and cross-functional teams to ensure assets are uploaded and structured according to enterprise standards.
  • Monitor and improve digital asset management data quality by identifying and resolving gaps in metadata, tagging, and asset organization.
  • Support digital asset management integration with downstream systems, such as content management systems and omnichannel platforms, to enable seamless content distribution.
  • Administer and maintain claims and references libraries within PromoMats, ensuring accuracy, completeness, and compliance.
  • Ensure claims are properly structured, tagged, and linked to supporting references and associated content.
  • Support modular content strategies by enabling claims reuse across assets and channels.
  • Partner with Regulatory, Medical, and Legal stakeholders to ensure claims governance standards are followed.
  • Perform ongoing quality checks to ensure claims remain current, valid, and aligned with approved references.
  • Support PRC/MRC processes by ensuring claims, references, and supporting documentation are accessible and compliant.
  • Develop and maintain reporting frameworks and dashboards to track content lifecycle performance, including review and approval cycle times, asset utilization and reuse, claims usage and distribution, workflow efficiency, and bottlenecks.
  • Analyze content and system data to generate actionable insights that inform process improvements and operational decisions.
  • Partner with stakeholders to define reporting requirements and translate business needs into scalable dashboards and metrics.
  • Ensure data integrity and consistency across digital asset management and claims datasets used for reporting.
  • Support leadership reporting needs with clear, concise, and actionable summaries of content performance.
  • Apply and enforce enterprise tagging and taxonomy standards across digital asset management and claims repositories.
  • Partner with taxonomy and tagging teams to evolve metadata frameworks that support automation, discoverability, and reporting.
  • Conduct regular audits to assess metadata completeness, accuracy, and adherence to standards.
  • Drive continuous improvement of data quality to support content reuse, analytics, and artificial intelligence enablement.
  • Support execution of PRC and MRC workflows by ensuring content, claims, and references are properly structured and ready for review.
  • Identify operational inefficiencies in review workflows and recommend improvements.
  • Partner with cross-functional stakeholders to ensure smooth content progression through review and approval processes.
  • Act as a key operational partner to Commercial, Medical, Regulatory, Legal, GCMT, and agency teams.
  • Provide guidance and support to content creators and reviewers on digital asset management, claims, and metadata best practices.
  • Translate business requirements into operational processes and system configurations where applicable.
  • Support onboarding and training of new users on digital asset management and claims management processes.
  • Ensure adherence to enterprise governance standards, standard operating procedures, and best practices for content management.
  • Contribute to development and refinement of operating procedures, guidelines, and documentation.
  • Monitor user adoption, feedback, and system usage to identify opportunities for improvement.
  • Drive continuous improvement initiatives to enhance efficiency, compliance, and user experience.
  • Provide operational guidance and subject matter expertise to cross-functional stakeholders, including Commercial, Medical, Regulatory, Legal, GCMT, and agency partners.
  • Coordinate and oversee work delivered by vendors or agency partners supporting digital asset management, claims management, and reporting activities.
Desired Qualifications
  • Experience supporting or enabling modular content and content reuse strategies.
  • Familiarity with reporting tools, dashboards, or data visualization platforms.

About the company

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

-6%

2 year growth

-1%
Associated Press
Oct 6th, 2026
Onco360 partners with BeOne Medicines to distribute Beqalzi for relapsed mantle cell lymphoma

Onco360, an independent specialty pharmacy, has been selected as a pharmacy partner by BeOne Medicines for Beqalzi (sonrotoclax). The drug is indicated for treating adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. Beqalzi is a BCL-2 protein inhibitor. In a Phase 1/2 study of 103 adult patients with relapsed/refractory mantle cell lymphoma, the drug achieved an overall response rate of 52.4%, with a median time to response of 1.9 months. The median duration of response was 15.8 months. Onco360 is headquartered in Louisville, Kentucky, and operates as a flagship brand of PharMerica Corporation.

Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.